NCT06982365Completed
Study to Investigate the Potential Health Benefits of Grapes Seeds Extract Supplementation in the Management of Elevated Blood Pressure or Stage 1 Hypertension
Study to Investigate the Potential Health Benefits of Grapes Seeds Extract Supplementation in the Management of Elevated Blood Pressure or Stage 1 Hypertension: A Pragmatic Randomized, Double-blind Placebo Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
This study is a pragmatic, randomized, double-blind, placebo-controlled trial aimed at evaluating the potential health benefits of Enovita® (standardized grape seed extract) supplementation in adults with elevated blood pressure or Stage 1 hypertension. The primary objective is to assess the impact of Enovita® on systolic and diastolic blood pressure over 8 weeks. Secondary outcomes include changes in mood, emotional well-being, perceived stress, lipid profile, and systemic inflammation. The study will also monitor the safety and tolerability of Enovita®.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 12 May 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 7 Nov 2025
- Lead sponsor
- Liaquat University of Medical & Health Sciences
- Diseases
- High blood pressure
- NCT number
- NCT06982365
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Aug 2025 to the primary completion date, 7 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Stage 2 Hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg) at screening.
- History of cardiovascular events (myocardial infarction, stroke) in the past 6 months.
- Known allergy to grape products.
Lab values
- Chronic kidney disease (eGFR \< 60 mL/min/1.73 m²).
- Diabetes mellitus (HbA1c ≥ 6.5%).
Other
- Current use of polyphenol supplements or similar herbal products.
- Pregnancy or breastfeeding.
- Participation in another clinical trial within the last 30 days.
Who the study is looking for
- Adults aged 30 to 65 years.
- Diagnosed with Elevated Blood Pressure (systolic 120-129 mmHg and diastolic \<80 mmHg) or Stage 1 Hypertension (systolic 130-139 mmHg or diastolic 80-89 mmHg), according to American Heart Association guidelines.
- No use of antihypertensive medication in the past 3 months.
- Willing to comply with study procedures and follow-up visits.
- Able to provide written informed consent.
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liaquat University of Medical & Health Sciences (LUMHS) Coordinator of this site? Confirm its status | Jamshoro | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.